GSK wins Zantac case and vows to fight other claims

7 August 2024

A jury in an Illinois state court has found that UK drugmaker GSK (LSE: GSK) is not liable for causing a plaintiff’s colorectal cancer.

This marks the latest legal win for GSK against claims that the heartburn medication Zantac (ranitidine) causes cancer. The London-based company is one of the firms now being sued because they have sold the product over the years, along with Pfizer (NYSE: PFE), Boehringer Ingelheim, Sanofi (Euronext: SAN) and others.

According to GSK, the verdict in the Illinois case is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. The company has cited 16 epidemiological studies looking at human data regarding the use of ranitidine in defense of its position.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK